• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1

    12/18/24 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary
    Get the next $EVH alert in real time by email

    Longtime CMO Dr. Andrew Hertler to serve as senior advisor and CMO emeritus.

    WASHINGTON, Dec. 18, 2024 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, announced the appointment of Dr. Von Nguyen as Chief Medical Officer, effective January 1, 2025.

    Dr. Nguyen joined Evolent as Chief Clinical Officer in July 2024 after serving as clinical lead for population health at Google. Among other previous roles, he has been Chief Medical Officer at Blue Cross North Carolina, Deputy Associate Director of Policy and Strategy at the Centers for Disease Control and Prevention, and Senior Advisor at the Centers for Medicare and Medicaid Services, where he helped design value-based programs in specialty and primary care. Trained as a primary care physician, he has worked at clinics for underserved communities in the U.S. and internationally.

    "Dr. Nguyen's unique mix of experiences in delivering patient care, shaping health policy and powering clinical innovation at scale position him well to lead Evolent's own clinical quality programs," said Evolent President Dan McCarthy. "As he has already demonstrated in his short time here, Von's background and skills, combined with his profound empathy for patients and his relentless passion for bringing fresh solutions to status quo challenges, will accelerate our efforts to create a higher-quality, more affordable and less fragmented healthcare system."

    Dr. Nguyen will succeed Dr. Andrew Hertler, who will move to a part-time role as senior advisor and CMO emeritus after more than a decade at Evolent. Dr. Hertler, a medical oncologist with more than 40 years in the field, will focus on advancing innovation for Evolent's oncology management solution.

    "Dr. Hertler is a giant in the field of value-based specialty care and improving patient outcomes, and I am honored to succeed him," said Dr. Nguyen. "I came to Evolent to help accelerate our mission of making care simpler, higher quality, more affordable and more connected for patients dealing with complex health conditions. Our team of over 1,500 doctors, nurses and allied clinicians wake up every day focused on this mission, and I look forward to working with them in my new role to build on Dr. Hertler's strong legacy in the future."

    Evolent Health Logo (PRNewsfoto/Evolent Health)

    About Evolent

    Evolent (NYSE:EVH) specializes in better health outcomes for people with complex conditions through proven solutions that make healthcare simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in healthcare nationally. Learn more about how Evolent is changing the way healthcare is delivered by visiting evolent.com.

    Contacts

    Media: Jamie Manfuso, [email protected] 

    Investors: Seth R. Frank, [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evolent-announces-dr-von-nguyen-as-incoming-chief-medical-officer-effective-january-1-302335408.html

    SOURCE Evolent Health, Inc.

    Get the next $EVH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVH

    DatePrice TargetRatingAnalyst
    1/10/2025$15.00Buy
    Needham
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    4/22/2024$40.00Buy
    Citigroup
    3/1/2024$45.00Outperform
    Oppenheimer
    1/3/2024$39.00Overweight
    Barclays
    More analyst ratings

    $EVH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Guertin Shawn M was granted 21,979 shares (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      6/9/25 7:18:32 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • New insider Guertin Shawn M claimed no ownership of stock in the company (SEC Form 3)

      3 - Evolent Health, Inc. (0001628908) (Issuer)

      6/9/25 7:17:22 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary
    • Director Jelinek Richard M was granted 21,979 shares, increasing direct ownership by 152% to 36,437 units (SEC Form 4)

      4 - Evolent Health, Inc. (0001628908) (Issuer)

      6/9/25 7:14:47 AM ET
      $EVH
      Other Consumer Services
      Consumer Discretionary